Previous work demonstrated that Ptpn2 silencing in B16F10 melanoma cells sensitized them to anti-PD-1 therapy in vivo by increasing IFNγ-induced antigen presentation and T-cell activation, culminating in inhibition of tumor growth (17). This evidence concerns the gene PDCD1 and neoplasm.